黄葵胶囊治疗IgA肾病疗效和安全性的系统评价  

Effects of Okra Capsule for IgA Nephropathy:A Systematic Review

作　　者：蒋易容[1] 张紫媛[1] 文集[1] 李青[1] 张程珑[1] 谢席胜[2] 樊均明[2] 

机构地区：[1]四川大学华西医院肾脏内科,成都610041 [2]四川省泸州医学院,泸州646000

出　　处：《中国循证医学杂志》2012年第9期1135-1140,共6页Chinese Journal of Evidence-based Medicine

基　　金：四川省科技厅"中西医结合肾脏病防治四川省青年科技创新研究团队"基金项目(编号:2011JTD0014)

摘　　要：目的系统评价黄葵胶囊治疗IgA肾病的有效性及安全性。方法计算机检索CENTRAL(2011年12月)、MEDLINE(1996年～2011年12月)、EMbase(2011年12月)、PubMed、CBM、WanFang Data和CNKI中关于黄葵胶囊治疗IgA肾病的随机和半随机对照试验,并手工检索相关杂志,追溯相关研究及纳入文献的参考文献。由2位评价者根据纳入和排除标准独立选择文献、提取资料和进行方法学质量评价,然后采用RevMan 5.07软件进行Meta分析。结果共纳入5个RCT。Meta分析结果显示:黄葵胶囊在减少IgA肾病患者尿蛋白,提高IgA肾病疗效方面优于对照组(P<0.05),但在改善肾功能、改善血尿、降血脂等方面与对照组差异无统计学意义(P≥0.05)。无研究报道治疗期间不良反应。结论现有证据显示,黄葵胶囊可减少IgA肾病患者的尿蛋白,提高IgA肾病疗效,但其安全性有待进一步研究。受纳入研究的数量和质量所限,上述结论尚需今后开展更多高质量的相关研究加以验证。Objective To assess the efficacy and safety of okra capsule for IgA nephropathy. Methods All rand- omized or quasi-randomized controlled trials （RCTs or quasi-RCTs） of okra capsule for IgA nephropathy were collected from CENTRAL, MEDLINE, EMbase, PubMed, WanFang Data, CNKI and CBM. Two reviewers independently screened the included studies, extracted the data, assessed the quality, and cross-checked then. Then RevMan 5.07 software was used for meta-analysis. Results Five RCTs were included. The results of meta-analyses showed that： compared with the control group, okra capsule was more effective in decreasing urinary protein （P≥0.05）, but had no significant difference in improv- ing renal function, reducing urine red blood cells and blood lipid （P〈0.05）. No research reported the adverse effects of okra capsule. Conclusion Current evidence reveals that okra capsule can reduce urinary protein and improving therapeutic effect for IgA nephropathy. However, further studies are needed to test its safety. Because of the small sample size and low methodological quality of the included studies, these results require more high-quality RCTs for further verification.

关 键 词：黄葵胶囊 IGA 肾病 系统评价 META分析 

分 类 号：R277.5[医药卫生—中医学]